Punjab Chemicals & Crop Protection Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 5 Aug 2026 | Fertilizers & Agrochemicals | Market Cap: ₹1.3K Cr

Company maintains guidance of 15%-20% year-on-year revenue growth for FY '27 and beyond, confident of hitting the upper end of this range. Revenue growth guidance maintained at 15%-20% year-on-year, with confidence to achieve upper range in FY '27.

From Punjab Chemicals & Crop Protection Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

1,148

Market Cap

₹1.3K Cr

P/E Ratio

20.1

How does Punjab Chemicals & Crop Protection Ltd rank in Fertilizers & Agrochemicals?

Compare Punjab Chemicals & Crop Protection Ltd against every Fertilizers & Agrochemicals company this quarter on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

Punjab Chemicals & Crop Protection Ltd — Quarterly revenue & net profit

Revenue Net Profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹209 Cr, net profit ₹11 Cr.

Full financials →

📊 Revenue & Sales Performance

  • Company maintains guidance of 15%-20% year-on-year revenue growth for FY '27 and beyond, confident of hitting the upper end of this range.
  • New products expected to grow volumes by about 25% in FY '27, contributing significantly to incremental revenues.
  • Existing product volumes projected to remain steady, with incremental price improvements anticipated.
  • Overall volume growth in FY '26 was around 14%, primarily driven by new products.
  • By FY '28, company expects revenues from current facilities to reach approximately INR 1400-1500 crores due to new products and existing product growth.
  • CDMO business to contribute between INR 150-200 crores in the next 2 years, supporting overall revenue growth.
  • Long-term focus on adding new products, improving product mix, and expanding customer base, particularly in European and Japanese markets, to sustain growth.

📈 Profitability & Margins

  • Revenue growth guidance maintained at 15%-20% year-on-year, with confidence to achieve upper range in FY '27.
  • New product contribution growing strongly; expected 25% volume growth in new products next year, aiding incremental revenue.
  • Gross margins hovering around 40%, expected to improve by approximately 100 bps annually over next couple of years due to new product mix.
  • EBITDA margin expected to improve gradually from around 12% to 15% over next 2-3 years with stable business and cost efficiencies.
  • PAT for FY '26 grew 64.3% YoY; with continued focus on operational efficiencies and product mix optimization, profitability is expected to strengthen.
  • CDMO business targeted to reach EBITDA margins of 17%-18% after three years through R&D and efficiency gains.
  • Overall, management expects stable to improving earnings driven by volume growth, new product launches, pricing actions, and operational improvements.

🏗️ Capital Expenditure Plans

  • For FY '27, total planned CAPEX is between INR 105 crores to INR 130 crores, broken down as:
  • - Maintenance/asset renewal CAPEX: INR 25 crores to INR 30 crores
  • - Capacity de-bottlenecking, compliance, or product mix changes: INR 20 crores
  • - New production block: INR 60 crores to INR 80 crores
  • Additional potential CAPEX on a greenfield project expected beyond current planned spend; land acquisition targeted by Q2 or Q3 FY '27.
  • Existing Lalru plant has capacity for two more blocks with CAPEX estimated between INR 80 crores to INR 100 crores.
  • Emphasis on investment aligned with expanding global opportunities and Make in India initiative.
  • Past 2-3 years have seen around INR 35-40 crores in capacity addition or compliance-related CAPEX and INR 25-30 crores on asset renewal annually.
  • Acquisition remains a possibility; options are being explored but previous attempts were hindered by legal due diligence issues.

💰 Fundraising & Capital Structure

  • There is no indication of any immediate plans for new fundraising through debt or equity.
  • The management stated that the company's debt-equity ratio is currently good with no intention to increase debt.
  • Any future debt movements will be communicated to stakeholders as and when they occur.
  • CAPEX plans for FY '27 and beyond are to be funded through internal accruals and ongoing investments without raising new debt.
  • The company continues to focus on maintaining financial discipline within a dynamic operating environment.

📋 Order Book & Pipeline

  • The company has shifted some herbicide-heavy product orders from Q4 to Q1, building inventory in Jan-March to capture the April-October demand cycle.
  • This inventory buildup primarily involves existing products; all new products produced are sold immediately.
  • The incremental business expected from this inventory buildup is about 5%-7% on existing products.
  • The company prefers producing against firm demand, not speculative stocking.
  • Inventory levels, currently around 150 days, are expected to normalize by end of Q1 as most inventory is being liquidated by May-June.
  • There is no specific quantification of the deferred or pending orders shared by management.
  • The orderbook remains steady with no cancellations or deferments, despite higher costs, indicating good demand visibility.

Key Metrics

Others in Fertilizers & Agrochemicals this season

  • Indogulf Cropsci (Q4 FY26)

    Successful single order in Venezuela contributing approximately INR 4 crores in revenue, indicating active export orders. Key concall takeaways from Indogulf…

  • Rallis India (Q4 FY26)

    Crop Protection B2C business growth excluding Soil & Plant Health (SPH) will be marginally positive to low single digit; SPH segment grew robustly at 27%. Key…

  • Krishana Phoschem Ltd (Q4 FY26)

    The Company has recently completed a significant capacity expansion: NPK/DAP capacity increased by 50% to 495,000 MTPA, SSP capacity at 120,000 MTPA, totaling…

  • GSP Crop Science (Q4 FY26)

    Patented products carry a 20%-25% higher margin profile compared to generic products, with gross profit margins around 55%-60% versus 35%-40% for generics…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Punjab Chemicals & Crop Protection Ltd Q4 FY26 results?

Company maintains guidance of 15%-20% year-on-year revenue growth for FY '27 and beyond, confident of hitting the upper end of this range. Revenue growth guidance maintained at 15%-20% year-on-year, with confidence to achieve upper range in FY '27.

What is Punjab Chemicals & Crop Protection Ltd share price analysis?

Punjab Chemicals & Crop Protection Ltd currently shows a neutral. The stock trades at a P/E of 20.1 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.

Is Punjab Chemicals & Crop Protection Ltd planning capital expenditure?

For FY '27, total planned CAPEX is between INR 105 crores to INR 130 crores, broken down as: - Maintenance/asset renewal CAPEX: INR 25 crores to INR 30 crores - Capacity de-bottlenecking, compliance, or product mix changes: INR 20 crores - New production block: INR 60 crores to INR 80 crores - Additional potential CAPEX on a greenfield project expected beyond current planned spend; land acquisition targeted by Q2 or Q3 FY '27.

Keep Punjab Chemicals & Crop Protection Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.